Squarepoint’s Monopar Therapeutics MNPR Stock Holding History

Squarepoint’s Portfolio MNPR Stock Details MNPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-21,754	Closed	-$1.19M	–	4759
2026 Q1	$1.19M	Buy	21,754 +11,233	+107%	+$679K	﹤0.01%	2623
2025 Q4	$687K	Buy	+10,521	New	+$860K	﹤0.01%	2934

Other funds holding MNPR

Jupiter Topco New York $245B AUM

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

SVCM

Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Squarepoint's MNPR Position: Q2 2026 in Review

Squarepoint sold out of Monopar Therapeutics (MNPR) in Q2 2026, closing a stake of 21,754 shares — an estimated $1.19M sold.

Squarepoint first reported a position in MNPR in Q4 2025 and held it in 2 quarters. The position peaked at $1.19M in Q1 2026. 96 funds tracked by Wall St. Rank hold MNPR as of Q2 2026.

Squarepoint reported no remaining Monopar Therapeutics position as of Q2 2026 after selling out during the quarter.
Squarepoint sold 21,754 Monopar Therapeutics shares in Q2 2026, an estimated $1.19M.
Squarepoint first reported a position in Monopar Therapeutics in Q4 2025 and held it in 2 quarters.
Squarepoint's Monopar Therapeutics position peaked at $1.19M in Q1 2026.
96 funds tracked by Wall St. Rank held Monopar Therapeutics as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.